NP-G2-044

DB14995InvestigationalSmall molecule

NP-G2-044 is under investigation in clinical trial NCT03199586 (Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma)).

Formula / weight: C₂₁H₁₆F₃N₃O₂ · 399.373 g/mol (avg)
Code names: NP-G2-044

Resolves to

Compound

UNII1ER2O3UZ4WCAS1807454-59-6

Structure

InChIKeyXLLRLAABUFOJPC-UHFFFAOYSA-NSMILESCC1=C(C=CO1)C(=O)NC1=NN(CC2=CC=C(C=C2)C(F)(F)F)C2=CC=CC=C12

Targets

Q16658FSCN1

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with NP-G2-044, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account